News and Trends 20 Jul 2017 Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […] July 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune and inflammatory disease. Ablynx, based in Belgium, develops nanobodies, single-domain antibodies inspired on those of camels and llamas that have the advantage of being much smaller than standard antibodies. This technology has caught the attention of Sanofi, […] July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 20 Jul 2017 Video – DNA Molecular Combing for the Early Detection of Genetic Diseases It’s been more than a month since Refresh, but the topic of our last expert track is as current as ever: DNA analysis for the early detection of genetic diseases. Charles Caulliez, Director of Corporate Business Development at Genomic Vision, started his talk by introducing the company: In 2004, Aaron Bensimon (CEO) founded Genomic Vision as […] July 20, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 20 Jul 2017 SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer SHIVA01 and SHIVA02 are large-scale trials run in France to evaluate the efficacy of precision medicine that have created ripples in the oncology field. Although molecular alterations are shared among different types of cancer, drug development today is still mainly based on tumor localization. The only recent exception is MSD’s Keytruda (pembrolizumab) an antibody approved by […] July 20, 2017 - 5 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 FREE White Paper! All You need to Know about Omics and Body Fat What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […] July 19, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer Update (19/07/2017): Tiziana has enrolled its first patient with refractory hepatocellular carcinoma in the Phase IIa trial with milciblib. Results are expected in the fourth quarter of 2018. Published on 24/04/2017 Tiziana Life Sciences has received approval to start Phase II in Israel with its leading compound, a CDK inhibitor targeting one of the deadliest cancers. […] July 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 19 Jul 2017 The Humanities of Scientific Investment: Perspectives from Europe’s Top Biotech Hub Deep human connections are the key to success in business, and biotech is no exception. The secret to amplifying this effect? Women. Commenting on the personal dimension of business usually comes as an aside in broader discussions, but at the ON Helix conference in the Cambridge area last Thursday, Sharon Vosmek, CEO of Silicon Valley-based […] July 19, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that specializes in developing antibodies. Back in 2015, it struck a research collaboration with Baxalta, which has since been acquired Shire. The Irish pharma has now decided to […] July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 German Biotech Strikes License Deal with Japanese Dermatology Firm 4SC has granted an exclusive worldwide license to the Japanese dermatology firm Maruho on a class of compounds against the Kv1.3 ion channel. Under the agreement, 4SC could receive up to €105M in upfront and milestone payments plus royalties on future sales. The deal is part of the German company’s strategy to out license non-core […] July 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Jul 2017 Is DNA the Future? The Best Biotech Talks of the Year We’ve compiled our favorite talks of the year by some of the best leaders in the field about how biotech will change our lives in coming years. Biotech is rapidly advancing thanks to the huge improvements the technology to both read and write DNA has experienced in the past years. While devices become smaller and […] July 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2017 Israeli Biotech Partners with German Chem Giant to Develop Non-GMO Herbicide Resistance Kaiima and BASF have partnered to develop crops with new herbicide resistance traits using non-GMO genetic engineering technology. Kaiima Bio Agritech works on boosting crop performance by using the plant’s own DNA, without the need of introducing external genes. In order to leverage this technology, the company has partnered with the giant chemical company BASF to discover […] July 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2017 A Brand New Outlook on Induced Pluripotent Stem Cells In an exclusive interview with Dr David Hallett, we discover why iPS cells are the perfect replacement for human embryonic stem cells, what is so unique about them and the challenges researchers face in the field! Talk of using human stem cells to better understand and even cure diseases has been around for a few decades. […] July 17, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email